Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction

Thrombosis Research

Volumn 89, Issue 6, 1998, Pages 263-270

  Ye, Zhiyi ^a   Takano, Ryo ^a   Hayashi, Kaeko ^a   Ta, Thanh Van ^a   Kato, Hisao ^b   Kamikubo, Yuichi ^c   Nakahara, Yo ^c   Kumeda, Kosuke ^c   Hara, Saburo ^a  

^a KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Affinity; Anticoagulant activity; Desulfation; Factor Xa; Heparin; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT PROTEIN; ARGININE; BLOOD CLOTTING FACTOR 10A; HEPARIN; HEPARIN DERIVATIVE; SYNTHETIC PEPTIDE; TISSUE FACTOR PATHWAY INHIBITOR;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CHO CELL; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BINDING SITES; BLOOD COAGULATION; HEPARIN; HUMANS; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; SEQUENCE ANALYSIS;

EID: 0032520742     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00017-6     Document Type: Article

References (22)

1. Bourin M.L., Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 289:1993;313-330.
2. Van Boeckel C.A.A., Petitou M. The unique antithrombin III binding domain of heparin. A lead to new synthetic antithrombotics Angew Chem Ind Ed Engl. 32:1993;1671-1690.
3. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway system in health and disease. The role of factor VIIa and tissue factor pathway inhibitor Thromb Res. 79:1995;1-47.
4. Lormeau J.C., Herault J.P., Herbert J.M. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost. 76:1996;5-8.
5. Broze G.J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 46:1995;103-112.
6. Wun T.C., Kretzmer K.K., Girard T.J., Miletich J.P., Broze G.J. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitor domains. J Biol Chem. 263:1988;6001-6004.
7. Wesselschmidt R., Likert K., Huang Z., Broze G.J. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coag Fibrinol. 4:1993;661-669.
8. Petersen J.G.L., Meyn G., Rasmussen J.S., Christiansen L., Petersen J., Bjørn S.E., Jonassen I., Norfang G.O. Characterization of human tissue factor pathway inhibitor (TFPI) variants expressed in Saccharomyces cerevisae. J Biol Chem. 268:1993;13344-13351.
9. Nordfang G.O., Bjørn S.E., Valentin S., Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its angicoagulant activity. Biochemistry. 30:1991;10371-10376.
10. Enjyoji K., Miyata T., Kamikubo Y., Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor. A segment, Gly-212-Phe243, of the third Kunitz domain is a heparin-binding site Biochemistry. 34:1995;5725-5735.
11. Bitter T., Muir H.M. A modified uronic acid carbazole reaction. Anal Biochem. 4:1962;330-334.
12. Matsuo M., Takano R., Kamei-Hayashi K., Hara S. A novel regioselective desulfation of polysaccharide sulfates. Specific 6-O-desulfation with N,O-bis(trimethylsilyl)acetamide Carbohydr Res. 241:1993;209-215.
13. Inoue Y., Nagasawa K. Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res. 46:1976;87-95.
14. Danishefsky I. Desulfation of heparin. Whistler R.L. Methods in Carbohydrate Chemistry, Vol. 5. 1965;407-409 Academic Press, New York.
15. Jaseja M., Rej R.N., Sauriol F., Perlin A.S. Novel regio- and stereoselective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can J Chem. 67:1989;1449-1456.
16. Sasaki H., Hayashi A., Kitagaki-Ogawa H., Matsumoto I., Seno N. Improved method for the immobilization of heparin. J Chromatogr. 400:1987;123-132.
17. Fromm J.R., Hileman R.E., Caldwell E.E.O., Weiler J.M., Linhardt R.J. Differences in the interaction of heparin with arginine and lysine and the importance of those basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys. 323:1995;279-287.
18. Harenberg J., Malsch R., Heene D.L. Tissue factor pathway inhibitor. Proposed heparin recognition region Blood Coagul Fibrinol. 6:1995;S50-S56.
19. 1-antitrypsin for structure and function of serpins. Biochemistry. 28:1989;8951-8966.
20. Van Deerlin V.M.D., Tollefsen D.M. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of α-thrombin in the presence of glycosaminoglycans. J Biol Chem. 266:1991;20223-20231.
21. Faham S., Hileman R.E., Fromm J.R., Linhardt R.J., Rees D.C. Heparin structure and interactions with basic fibroblast growth factor. Science. 271:1996;1116-1120.
22. Mascotti D.P., Lohman T.M. Thermodynamics of charged oligopeptide-heparin interactions. Biochemistry. 34:1995;2098-2115.